VYYRF (Voyageur Pharmaceuticals) Long-Term Debt: $0.00 Mil (As of Feb. 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
14 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals Long-Term Debt?

Voyageur Pharmaceuticals VYYRF 14 Long-Term Debt is $0.00 Mil as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 14/100. The stock has 5 warning signs investors should review.

Voyageur Pharmaceuticals's Long-Term Debt for the quarter that ended in Feb. 2026 was $0.00 Mil.

Voyageur Pharmaceuticals's quarterly Long-Term Debt declined from Aug. 2025 ($0.03 Mil) to Nov. 2025 ($0.03 Mil) and declined from Nov. 2025 ($0.03 Mil) to Feb. 2026 ($0.00 Mil).

Voyageur Pharmaceuticals's annual Long-Term Debt stayed the same from Nov. 2023 ($0.03 Mil) to Nov. 2024 ($0.03 Mil) but then declined from Nov. 2024 ($0.03 Mil) to Nov. 2025 ($0.03 Mil).

Voyageur Pharmaceuticals  (OTCPK:VYYRF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Voyageur Pharmaceuticals Long-Term Debt Related Terms

Voyageur Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals Long-Term Debt Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.03 0.03 0.03

Voyageur Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.00
VYYRF
14GF Score
Voyageur Pharmaceuticals Ltd VYYRF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Voyageur Pharmaceuticals (VYYRF) has a Long-Term Debt of $0.00 Mil as of Feb. 2026.
Is Voyageur Pharmaceuticals' Long-Term Debt too high?
Voyageur Pharmaceuticals' current Long-Term Debt is $0.00 Mil. Overall, Voyageur Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' Long-Term Debt compare to ZTS and UTHR?
Voyageur Pharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Voyageur Pharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Voyageur Pharmaceuticals' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current Long-Term Debt is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
14GF Score

Get the complete analysis for VYYRF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price